Atrovent - a drug intended for the treatment of diseases of the respiratory system.
Release form and composition
Atrovent is produced in the form of a colorless transparent solution, which is practically free from particles, 20 ml each in glass dropper bottles.
One ml of the solution consists of 261 µg ipratropium bromide monohydrate and auxiliary substances - sodium and benzalkonium chloride, hydrochloric acid 1N, disodium edetate dihydrate and purified water.
Indications for use
The instructions to Atrovent indicated that the drug is prescribed in the treatment of bronchial asthma and chronic obstructive pulmonary disease.
The use of Atrovent is contraindicated in patients with hypersensitivity to the components of the medication.
With caution, the drug is prescribed in cases of prostatic hyperplasia, angle-closure glaucoma, urinary tract obstruction, during lactation, and children under six years of age.
Dosing and Administration
The dosage of the agent is determined by the doctor on an individual basis; usually, the Atrovent treatment regimen has the following form:
In cases of maintenance treatment, patients from 12 years old and adults are prescribed three or four inhalations with 40 drops of the drug, patients from six to 12 years old - three inhalations with 20 drops, children under six years old - 3-4 inhalations with 8-20 drops;
In acute bronchospasm, children as young as 12 years old and adults are prescribed inhalations with 2 ml of Atrovent, children 6–12 years old with 1 ml of the drug, and patients younger than 6 years old with 0.4–1 ml of the drug. The time interval between inhalations, the doctor determines individually for each patient.
Note that 1 ml of the drug is equal to 20 drops. Immediately before inhalation, the recommended dose of Atrovent is diluted with 0.9% sodium chloride solution until a total volume of 3-4 ml is obtained.
The instructions to Atrovent indicated that the drug most often causes the following side effects:
- Dry mouth, increased pulse rate and headache;
- Constipation, urinary retention and diarrhea;
- Nausea, vomiting and atrial fibrillation;
- Cough, paradoxical bronchospasm and local irritation;
- Skin rash, swelling of the lips, tongue and face;
- Supraventricular tachycardia, palpitations, and dizziness;
- Laryngism, angioedema and accommodation disturbance;
- Urticaria, itching and laryngeal spasm.
In case of accidental contact of Atrovent with eyes, paresis of accommodation, an increase in intraocular pressure, blurred vision and pupil dilation may occur.
The tool is not intended for emergency relief of asthma attacks, as it has a bronchodilator effect later than β-adrenostimulants.
In cases of use of Atrovent in patients with cystic fibrosis, the risk of gastrointestinal motility delays increases.
If after a few days of drug treatment the patient's condition worsens or there is no positive effect after inhalations, the doctor must change the treatment regimen.
The combined use of Atrovent for inhalation in combination with Ambroxol, Bromhexin and Berotec is allowed.
Due to the fact that the tool contains disodium edetate and benzalkonium chloride, which in some cases can cause a narrowing of the lumen of the bronchi, Atrovent can serve as the occurrence of bronchospasm.
The drug is synonymous with drugs Iprovent and Ipratropium Steri-Neb.
Atrovent analogs are such drugs as:
- Sibri Brizhaler.
Terms and conditions of storage
According to the instructions, Atrovent should be stored in a dry place out of reach of children, well ventilated and protected from light, at a temperature not exceeding 30 ° C.
The drug is released from pharmacies by prescription, its shelf life is three years. After the expiration date of the tool must be disposed of.